QBL subsidiary MCL on MMJ DRUG DEVELOPMENT strategy;
QBL subsidiary MCL on MMJ DRUG DEVELOPMENT strategy;
QBL:MCL implementing CannTab drug development strategy. MCL, in conjunction with Certara, a pharmaceutical consulting firm, have developed a drug development strategy for the distribution of CannTab XR medication in the Australian market.
The Certara team includes Dr Andreas Wallnoefer, who held a significant tenure as Global Head of Early Development at Roche and Dr Graham Scott, who prior to Certara, was European lead of Clinical Pharmacology at Takeda. The drug development team is led by Andrew Kavasilas, MCL’s technical expert on cannabis.
See QBL-board on crucial news this week!
Here you have the possibility to take advantage on facts and info from QBL. Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until next week. Contact information to the QBL Investor service, who can reply on questions.
https://www.queenslandbauxite.com/
1
Robert
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding Tryg's Share Buyback Program Tryg A/S has made headlines with its recent announcement regarding a significant share buyback program. This initiative reflects the company's strategic approach to enhancing shareholder value. Announced on December 4th, Tryg has committed to a buyback program valued at up to DKK 2.0 billion and operates under the guidelines set...
Continue Reading
Skyscanner's Insightful Travel Trends for 2026 As we look toward 2026, travelers are set to embrace a new era of journeys, one that focuses on personal experiences and purposeful travel. From exploring culinary delights to engaging with local cultures, here are the seven trends transforming the way people explore the world. Embracing Beauty Rituals on the Road Travelers...
Continue Reading
Nvidia's earnings were turning heads back in 2024, when the stock was on fire. It had shot up a jaw-dropping 172% year-to-date after an insane 239% hike the previous year. Traders knew this wasn't just luck; it was about consistently beating analyst expectations and fueling investor excitement. Nvidia Earnings: A History of Beats Historically, firms in the S&P 500 tend to...
Continue Reading
Electric Rays’ Surprising Defense Mechanism Recent research has revealed that electric rays employ a remarkable defense strategy against predators, particularly sharks. These creatures are not only bold in their approach but also possess a unique ability to generate electric discharges that they utilize to ward off threats in their environment. Understanding the...
Continue Reading
Understanding the Growth of Reinsurance Group Over the past five years, Reinsurance Group of America Inc (NYSE: RGA) has significantly outshined the market, achieving an impressive annualized outperformance of 3.25%. This translates into an attractive average annual return of 17.93%, which illustrates the company’s solid position within the finance sector. What Would a...
Continue Reading